congresos y reuniones científicas
Controlled release of an anti-inflammatory protein
GUERRIERI DIEGO; CHIAPPETTA DIEGO; MAFFIA PAULO; AMIANO NICOLAS; CHULUYAN EDUARDO
Ciudad de Buenos Aires, Argentina
Congreso; XXXIX reunion cientifica anual,asociacion argentina de farmacologia experimental; 2007
ASOCIACION ARGENTINA DE FARMACOLOGIA EXPERIMENTAL
Secretory leucoprotease inhibitor (SLPI) is an 11,7 kDa non-glycosylated protein which is expresed in mucosa. SLPI forms inhibitory complexes with serine proteases, mainly neutrophilic elastase, and also has anti-inflammatory properties. SLPI is rapidly degradated when given parenterally. Our aim was to develop a carrier system to deliver SLPI in a sustained way. For this purpose, SLPI was encapsulated in microspheres of PCL (poly-å-caprolactone). In order to evaluated the release of SLPI in vitro 30 mg of microspheres were resuspended in PBS and a specific ELISA assay was performed. SLPI was released over a period of 30 days with a burst phase at day 15. This SLPI also showed anti-trypsin activity. Furthermore, the proliferation of IL-2 stimulated lymphocytes was inhibited by released SLPI (44±10 %). Finally, to evaluate the anti-inflammatory activity in vivo, Balb/c mice were treated with pristane in the foot pad and microspheres carrying SLPI were delivered s.c. simultaneously. These mice showed a significantly lower foot pad edema compared with control mice (p<0.05). In conclusion, these results indicate that SLPI encapsulated in microspheres of PCL is released in a prolonged and sustained way, maintaining its biological activity in vitro and in vivo.